Comput Biol Med. 2025 Nov 1;198(Pt B):111240. doi: 10.1016/j.compbiomed.2025.111240. Online ahead of print.
ABSTRACT
Glioblastoma is the most common and deadly brain cancer, known for its rapid progression and heterogeneity at microscopic and macroscopic levels. This heterogeneity is influenced by factors such as tumor cell density, involvement of normal tissue, and gene expression profiles. Mutations in EGFR gene are associated with shorter recurrence intervals and poorer survival outcomes in GBM patients. Non-invasive imaging techniques like MRI can provide valuable insights into EGFR mutations. To reduce the risks of brain biopsies and sampling errors, this study introduces an AI-based decision support system (DSS) for classifying EGFR mutations in GBM patients through automated segmentation of tumorous regions using MRI. The DSS employs deep neural networks (Inception ResNet-v2, DenseNet-121, and ResNet-50) trained on a GBM dataset from Memorial Hospital in Istanbul, which includes three MRI input types: expert segmented, without segmentation, and without tumor. Information criteria (IC) were used to guide model selection by balancing predictive performance and structural complexity. DenseNet-121 showed superior performance, with accuracy scores of 0.952, 0.942, and 0.938 for expert segmented, without segmentation, and absence of tumor inputs, respectively. Precision and recall metrics were also highest for DenseNet-121, especially with expert-segmented inputs. A multivariate statistical analysis confirmed significant differences across model performances. The results underscore the value of integrating information criteria into deep learning pipelines to enhance model robustness and interpretability in medical imaging applications.
PMID:41176824 | DOI:10.1016/j.compbiomed.2025.111240
